JP2023036695A5 - - Google Patents

Download PDF

Info

Publication number
JP2023036695A5
JP2023036695A5 JP2022198455A JP2022198455A JP2023036695A5 JP 2023036695 A5 JP2023036695 A5 JP 2023036695A5 JP 2022198455 A JP2022198455 A JP 2022198455A JP 2022198455 A JP2022198455 A JP 2022198455A JP 2023036695 A5 JP2023036695 A5 JP 2023036695A5
Authority
JP
Japan
Prior art keywords
compound
hydrocarbyl
different
same
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022198455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023036695A (ja
JP7419486B2 (ja
Filing date
Publication date
Priority claimed from US13/940,016 external-priority patent/US10017736B2/en
Application filed filed Critical
Publication of JP2023036695A publication Critical patent/JP2023036695A/ja
Publication of JP2023036695A5 publication Critical patent/JP2023036695A5/ja
Application granted granted Critical
Publication of JP7419486B2 publication Critical patent/JP7419486B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022198455A 2012-07-13 2022-12-13 τリン酸化を阻害する方法 Active JP7419486B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261671235P 2012-07-13 2012-07-13
US61/671,235 2012-07-13
US201361789180P 2013-03-15 2013-03-15
US61/789,180 2013-03-15
US13/940,016 2013-07-11
US13/940,016 US10017736B2 (en) 2012-07-13 2013-07-11 Method of inhibiting tau phosphorylation
JP2018189789A JP2019031520A (ja) 2012-07-13 2018-10-05 τリン酸化を阻害する方法
JP2021089538A JP2022000421A (ja) 2012-07-13 2021-05-27 τリン酸化を阻害する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021089538A Division JP2022000421A (ja) 2012-07-13 2021-05-27 τリン酸化を阻害する方法

Publications (3)

Publication Number Publication Date
JP2023036695A JP2023036695A (ja) 2023-03-14
JP2023036695A5 true JP2023036695A5 (cg-RX-API-DMAC7.html) 2023-06-26
JP7419486B2 JP7419486B2 (ja) 2024-01-22

Family

ID=49914489

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015521820A Active JP6417324B2 (ja) 2012-07-13 2013-07-11 τリン酸化を阻害する方法
JP2018000198A Active JP6630374B2 (ja) 2012-07-13 2018-01-04 τリン酸化を阻害する方法
JP2018189789A Pending JP2019031520A (ja) 2012-07-13 2018-10-05 τリン酸化を阻害する方法
JP2021089538A Pending JP2022000421A (ja) 2012-07-13 2021-05-27 τリン酸化を阻害する方法
JP2022198455A Active JP7419486B2 (ja) 2012-07-13 2022-12-13 τリン酸化を阻害する方法

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2015521820A Active JP6417324B2 (ja) 2012-07-13 2013-07-11 τリン酸化を阻害する方法
JP2018000198A Active JP6630374B2 (ja) 2012-07-13 2018-01-04 τリン酸化を阻害する方法
JP2018189789A Pending JP2019031520A (ja) 2012-07-13 2018-10-05 τリン酸化を阻害する方法
JP2021089538A Pending JP2022000421A (ja) 2012-07-13 2021-05-27 τリン酸化を阻害する方法

Country Status (6)

Country Link
US (7) US10017736B2 (cg-RX-API-DMAC7.html)
EP (1) EP2882428B1 (cg-RX-API-DMAC7.html)
JP (5) JP6417324B2 (cg-RX-API-DMAC7.html)
DK (1) DK2882428T3 (cg-RX-API-DMAC7.html)
ES (1) ES2716049T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014011917A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882428B1 (en) 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
EP2872899B1 (en) * 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
GB201312499D0 (en) * 2013-07-12 2013-08-28 Isis Innovation Therapeutic compounds
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
AU2017340403B2 (en) 2016-10-05 2022-03-17 The United States as Represented by the Department of Veterans Affairs Small molecule AMPK activators
US12186307B2 (en) 2019-02-13 2025-01-07 Yale University Methods of treating epilepsy
JP7895041B2 (ja) * 2019-02-21 2026-07-27 フィラナ セラピューティクス インコーポレイテッド Ｆｌｎａ結合化合物及びその塩酸塩の固体多形
AU2020345766A1 (en) 2019-09-10 2022-03-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for increasing level of phosphorylated AMPK protein
WO2021145372A1 (ja) * 2020-01-15 2021-07-22 国立大学法人東海国立大学機構 進行性核上性麻痺の治療
WO2022098700A1 (en) * 2020-11-03 2022-05-12 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4
CN114252324B (zh) * 2022-03-02 2022-05-13 中国人民解放军军事科学院军事医学研究院 一种方便使用的多孔脑片孵育装置
WO2024151661A2 (en) * 2023-01-10 2024-07-18 Washington University Methods of decreasing pathological neuroinflammation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
US3723442A (en) 1970-12-31 1973-03-27 Yoshitomi Pharmaceutical 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes
US4981858A (en) 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
ATE122353T1 (de) 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
DE69412067T2 (de) 1993-01-28 1999-03-25 Merck & Co., Inc., Rahway, N.J. Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
EP1019410A1 (en) 1995-11-23 2000-07-19 MERCK SHARP & DOHME LTD. Spiro-piperidine derivatives and their use as tachykinin antagonists
ES2306482T3 (es) 1997-08-28 2008-11-01 Novartis Ag Antagonistas de antigeno-1 funcion con funcion de linfocito.
AU765142B2 (en) * 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
WO2001040261A1 (en) 1999-12-01 2001-06-07 Ortho-Mcneil Pharmaceutical, Inc. Method of diagnosing neurodegenerative disease
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
CA2454785C (en) 2001-07-23 2010-09-07 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
AU2003223098A1 (en) 2002-01-14 2003-09-02 Sun Pharmaceutical Industries Limited Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone
JP4584706B2 (ja) 2002-05-03 2010-11-24 イスラエル インスティチュート フォー バイオロジカル リサーチ 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
US20070149543A1 (en) 2003-01-29 2007-06-28 Stockwell Brent R Agents For Treating Neurodegenerative Diseases
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
DE102004014296A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
AU2005244852B2 (en) * 2004-05-12 2011-09-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007041855A1 (en) 2005-10-13 2007-04-19 Waratah Pharmaceuticals, Inc. Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
FR2905009A1 (fr) 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
US20100280057A1 (en) * 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
US8614324B2 (en) 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8722851B2 (en) 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
US20100279996A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
EP2488177B1 (en) * 2008-10-31 2016-10-12 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
US8580808B2 (en) 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
WO2010084499A2 (en) 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
WO2010088400A1 (en) 2009-01-28 2010-08-05 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases
US20100280061A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
TWI374662B (en) * 2009-05-18 2012-10-11 Novatek Microelectronics Corp Image processing circuit and method thereof
US8580809B2 (en) 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
EP2882428B1 (en) 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
US20140094482A1 (en) * 2012-08-16 2014-04-03 George B. Thornton Benzazocine-ring compound inhibition of tau hyperphosphorylation
JP7895041B2 (ja) 2019-02-21 2026-07-27 フィラナ セラピューティクス インコーポレイテッド Ｆｌｎａ結合化合物及びその塩酸塩の固体多形

Similar Documents

Publication Publication Date Title
JP2022000421A5 (cg-RX-API-DMAC7.html)
JP2015523385A5 (cg-RX-API-DMAC7.html)
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
NZ590784A (en) Pyrazolopyridine kinase inhibitors
ZA200403087B (en) MCH antagonists for the treatment of obesity.
ATE300521T1 (de) Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
RU98118568A (ru) Триарильные соединения
RU2008134534A (ru) 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов
RU2004130427A (ru) Производные нитрозодифениламина и их фармацевтическое применение против патологий окислительного стресса
RU2000127751A (ru) Противоопухолевое средство
RU2000105266A (ru) Производные 1-(n-фениламиноалкил)-пиперазина, замещенные в положении 2 фенильного кольца
JP2008515913A5 (cg-RX-API-DMAC7.html)
JP2008515913A (ja) 多発性嚢胞腎の治療のための方法
JP2010501478A5 (cg-RX-API-DMAC7.html)
HRP20110332T1 (hr) TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3
JP2023533982A5 (cg-RX-API-DMAC7.html)
RU2002103876A (ru) АМИНОБЕНЗОФЕНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕРЛЕЙКИНА IL-1β И ФАКТОРА НЕКРОЗА ОПУХОЛЕЙ TNF-α
KR910004568A (ko) 치환 n-(퀴놀린-2-일-메톡시)벤질-술포닐우레아
RU2007112501A (ru) Бензимидазольные производные, содержащие их композиции, их получение и применение
RU2015101211A (ru) Производное имидазопиридина, используемое для лечения сахарного диабета
RU2006117627A (ru) Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений
US4442084A (en) Analgesic and myotonolytic preparations
EP0751772A1 (en) New use of quinoline-3-carboxamide compounds
JP2005515169A5 (cg-RX-API-DMAC7.html)
JPH10507446A (ja) ビス−２−アミノピリジン類、その製造方法及び寄生虫感染を制御するためのその用途